Stock Events

Stock Events

Hemogenyx Pharmaceuticals 

$2.33
30
+$2.29+5,725% Monday 20:00

Statistics

Day High
0.04
Day Low
0.04
52W High
2.33
52W Low
0.04
Volume
25,000
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28JunExpected
Q2 2021
Q1 2022
Q2 2022
Q1 2023
Q2 2023
Q1 2024
Q1 2024
-0.01
-0.01
-0
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.07MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HOPHF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is involved in gene editing, a technology Hemogenyx could utilize in developing its therapies for blood-related diseases.
Sangamo Therapeutics
SGMO
Mkt Cap104.07M
Sangamo Therapeutics works on genomic medicine, including gene therapy, which competes with Hemogenyx's approach to treating blood disorders.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals is pioneering RNAi therapeutics, a novel form of treatment that could overlap with Hemogenyx's target diseases.
Novartis
NVS
Mkt Cap297.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for blood disorders, directly competing with Hemogenyx's focus area.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences has a strong presence in the treatment of blood diseases, including cell therapies, which puts it in competition with Hemogenyx.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which involve blood disorders that could be targeted by Hemogenyx's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals engages in creating new therapies for genetic diseases, including blood disorders, competing with Hemogenyx's research focus.
AMGEN
AMGN
Mkt Cap189.22B
Amgen has a diverse portfolio in biotechnology, including treatments for blood disorders, making it a competitor to Hemogenyx.
Pfizer
PFE
Mkt Cap153.13B
Pfizer, with its extensive research and development in various therapeutic areas, including blood disorders, competes with Hemogenyx's niche focus.

About

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Vladislav Sandler Ph.D.
Employees
16
Country
United States
ISIN
GB00BQVXM815

Listings

STU
DE
5HU0.STU
F
DE
5HU0.F
LSE
GB
HEMO.LSE
OTC Link
US
HOPHF

0 Comments

Share your thoughts

FAQ

What is Hemogenyx Pharmaceuticals stock price today?▼
The current price of HOPHF is $2.33 USD — it has increased by +5,725% in the past 24 hours. Watch Hemogenyx Pharmaceuticals stock price performance more closely on the chart.
What is Hemogenyx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Hemogenyx Pharmaceuticals stocks are traded under the ticker HOPHF.
What were Hemogenyx Pharmaceuticals earnings last quarter?▼
HOPHF earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Hemogenyx Pharmaceuticals revenue for the last year?▼
Hemogenyx Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Hemogenyx Pharmaceuticals net income for the last year?▼
HOPHF net income for the last year is -7.07M USD.
How many employees does Hemogenyx Pharmaceuticals have?▼
As of April 13, 2026, the company has 16 employees.
In which sector is Hemogenyx Pharmaceuticals located?▼
Hemogenyx Pharmaceuticals operates in the Health & Wellness sector.
When did Hemogenyx Pharmaceuticals complete a stock split?▼
The last stock split for Hemogenyx Pharmaceuticals was on December 13, 2024 with a ratio of 1:400.
Where is Hemogenyx Pharmaceuticals headquartered?▼
Hemogenyx Pharmaceuticals is headquartered in London, United States.